| $385M | ||
| $350M | ||
| $215M | ||
| $100M | ||
| $88M | ||
| $82M |
Buys | $0 | 0 | – |
Sells | $0 | 0 | – |
MIRA Pharmaceuticals, Inc. operates as a clinical development stage biopharmaceutical company. The company focuses on the development and commercialization of a new molecular synthetic tetrahydrocannabinol (THC) analog under investigation for the treatment of adult patients with anxiety and cognitive decline typically associated with early-stage dementia. It is developing MIRA1a, a synthetic cannabinoid analog to treat anxiety and chronic pain by targeting the cannabinoid type 1 and type 2 receptors. The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Baltimore, Maryland.
Over the last 12 months, insiders at MIRA Pharmaceuticals, Inc. have bought $0 and sold $0 worth of MIRA Pharmaceuticals, Inc. stock.
On average, over the past 5 years, insiders at MIRA Pharmaceuticals, Inc. have bought $8,176 and sold $525,649 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 8,700 shares for transaction amount of $8,176 was made by Aminov Erez (Chief Executive Officer) on 2024‑05‑21.
| 2024-11-20 | Sale | Aminov Erez | Chief Executive Officer | 44,590 0.2651% | $1.27 | $56,629 | 0.00% | |
| 2024-11-19 | Sale | Aminov Erez | Chief Executive Officer | 55,410 0.3605% | $1.39 | $77,020 | -10.00% | |
| 2024-08-28 | Sale | McNulty Brian Patrick | 10 percent owner | 200,000 1.8349% | $1.96 | $392,000 | -29.65% | |
| 2024-05-21 | Aminov Erez | Chief Executive Officer | 8,700 0.0383% | $0.94 | $8,176 | +13.73% |
| McNulty Brian Patrick | 10 percent owner | 2540270 6.0662% | $3.07M | 0 | 1 | |
| Aminov Erez | Chief Executive Officer | 1061200 2.5341% | $1.28M | 1 | 2 | +13.73% |
$364,217,072 | 28 | 9.11% | $26.64B | |
$6,224,380 | 25 | 3.58% | $582.04B | |
$1,922,773,492 | 23 | 18.04% | $929.28B | |
$23,339,596 | 21 | 6.64% | $120.31B | |
$28,542,809 | 19 | 26.39% | $388.43B | |
$2,523,290 | 18 | -0.87% | $151.25B | |
$17,274,470 | 17 | 3.96% | $285.86B | |
$356,328 | 15 | -42.83% | $70.73M | |
$3,170,734 | 10 | 3.98% | $197.41B | |
$3,933,798 | 8 | 12.50% | $179.99B | |
$252,679 | 2 | 0.47% | $1.65B | |
MIRA Pharmaceuticals, Inc. (MIRA) | $8,176 | 1 | 13.73% | $50.67M |
| Increased Positions | 10 | +34.48% | 963,673 | +69.07% |
| Decreased Positions | 8 | -27.59% | 142,375 | -10.2% |
| New Positions | 2 | New | 332,777 | New |
| Sold Out Positions | 6 | Sold Out | 108,697 | Sold Out |
| Total Postitions | 31 | +6.9% | 2M | +58.87% |
| Cross Staff Investments Inc | $536.00 | 0.86% | 359,401 | 0 | 0% | 2025-09-30 |
| Vanguard Group Inc | $303.00 | 0.49% | 203,643 | +85,819 | +72.84% | 2025-09-30 |
| Geode Capital Management, Llc | $203.00 | 0.33% | 136,440 | +1,145 | +0.85% | 2025-09-30 |
| Blackrock, Inc. | $164.00 | 0.26% | 109,769 | +109,769 | New | 2025-09-30 |
| Suncoast Equity Management | $154.00 | 0.25% | 103,289 | 0 | 0% | 2025-09-30 |
| First American Bank | $75.00 | 0.12% | 50,000 | +30,000 | +150% | 2025-09-30 |
| State Street Corp | $73.00 | 0.12% | 49,100 | 0 | 0% | 2025-09-30 |
| Renaissance Technologies Llc | $70.00 | 0.11% | 46,700 | +46,700 | New | 2025-09-30 |
| Two Sigma Investments, Lp | $68.00 | 0.11% | 45,703 | +25,816 | +129.81% | 2025-09-30 |
| J.W. Cole Advisors, Inc. | $68.00 | 0.11% | 45,501 | +4,846 | +11.92% | 2025-09-30 |